What happened: The NHS will now provide abiraterone to around 8,000 men newly diagnosed with prostate cancer each year whose disease is confined to the prostate. This drug works by cutting off hormones that fuel cancer growth.
Why it matters:
- The expanded access could save thousands of lives by treating cancer earlier.
- It benefits men with non-metastatic prostate cancer across England, improving treatment options.
MNN Take: Offering abiraterone at an earlier stage aims to improve survival rates by targeting cancer before it spreads, reflecting a significant development in NHS cancer care.
Sources: Guardian UK